Emily Menendez

GU Oncology Now

The co-expression extrapolation (COXEN) model is used to select genes for predicting tumor cell response to a specific drug treatment. Researchers in a phase 2 trial of neoadjuvant gemcitabine-cisplatin (GC) or dose-dense methotrexate, vinblastine, adriamycin, and cisplatin (ddMVAC) in muscle-invasive bladder cancer (MIBC) used the COXEN model to determine its efficacy at <a href="https://www.sciencedirect.com/science/article/abs/pii/S0302283823029457" target="_blank" rel="noopener">predicting patient response to neoadjuvant chemotherapy.</a>A total of 167 patients with MIBC were included in the trial and randomized to receive either ddMVAC every 14 days or GC every 21 days, each for 4 cycles. Patient COXEN scores were analyzed for their association with event-free survival (EFS) and overall survival (OS) and by treatment arm. EFS was defined as progression or death before scheduled surgery, patient decision not to undergo surgery, recurrence, or death due to any cause after surgery. Cox regression analysis was used to evaluate the COXEN score or treatment arm association with EFS and OS.The GC COXEN scores had a hazard ratio (HR) of 0.45 (95% CI, 0.20-0.99; P=.047) in both arms pooled together, but the scores were not significantly prognostic for OS or EFS in their respective arms. In the intent-to-treat analysis (n=226), no significant difference was found between ddMVAC and GC for OS (HR, 0.87; 95% CI, 0.54-1.40; P=.57) or EFS (HR, 0.86; 95% CI, 0.59-1.26; P=.45).In patients who underwent surgery, pathologic response (pT0 vs downstaging vs no response) was strongly related to superior postsurgical survival, with a 5-year OS rate of 90%, 89%, and 52%, respectively.The COXEN GC score is a useful tool for predicting response in patients receiving cisplatin-based neoadjuvant treatment, providing estimates of OS and EFS for GC and ddMVAC in the MIBC population. Pathologic response (&lt;pT2) performed well as an intermediate end point and should be used in future phase 2 trials.

COXEN Model Determines Efficacy of Patient Response to Neoadjuvant Chemotherapy

Muscle Invasive Urothelial Carcinoma

Researchers in a phase 2 trial used the COXEN model to determine its efficacy at predicting patient response to neoadjuvant chemotherapy.

COXEN Model Determines Efficacy of Neoadjuvant Chemotherapy

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe